Navigation Links
Regulus Therapeutics and Collaborators from NYU Langone Medical Center Publish New Data Demonstrating Clearance of Cholesterol from Bloodstream and Reduction of Atherosclerotic Plaques through Inhibition of microRNA-33
Date:6/6/2011

control, metabolism, viral replication, stem cell differentiation and human development. Most microRNAs are conserved across multiple species, indicating the evolutionary importance of these molecules as modulators of critical biological pathways. Indeed, microRNA expression, or function, has been shown to be significantly altered in many disease states, including cancer, heart failure and viral infections. Targeting microRNAs with anti-miRs, antisense oligonucleotide inhibitors of microRNAs, or miR-mimics, double-stranded oligonucleotides to replace microRNA function opens potential for a novel class of therapeutics and offers a unique approach to treating disease by modulating entire biological pathways. To learn more about microRNAs, please visithttp://www.regulusrx.com/microrna/microrna-explained.php.

About Regulus Therapeutics Inc.

Regulus Therapeutics is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. Regulus is using a mature therapeutic platform based on technology that has been developed over 20 years and tested in more than 5,000 humans. In addition, Regulus works with a broad network of academic collaborators and leverages the oligonucleotide drug discovery and development expertise of its founding companies, Alnylam Pharmaceuticals (NASDAQ: ALNY) and Isis Pharmaceuticals (NASDAQ: ISIS).Regulus is advancing microRNA therapeutics towards the clinic in several key areas including hepatitis C infection, immuno-inflammatory diseases, fibrosis, oncology, and cardiovascular/metabolic diseases. Regulus' intellectual property estate contains both the fundamental and core patents in the field and includes over 600 patents and more than 300 pending patent applications pertaining primarily to chemical modifications of oligonucleotides targeting microRNAs for therapeutic applications. In April 2
'/>"/>

SOURCE Regulus Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... , May 28, 2015  Eli Lilly and Company (NYSE: ... previously announced cash tender offer for up to $1.6 billion ... Holders of notes who tendered, and did not ... New York City time, on May 27, ... purchase by Lilly, are eligible to receive the total consideration. ...
(Date:5/28/2015)... May 28, 2015 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or ... second quarter and three and six months ended March 31, ... and in accordance with International Financial Reporting Standards ("IFRS"). ... net loss of $5.9 million ($0.35 per common share) for ... a net loss of $0.4 million ($0.03 per common share) ...
(Date:5/28/2015)... Research and Markets ( ... Jain PharmaBiotech,s new report  "RNAi - Technologies, ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , ... the use of double stranded RNA (dsRNA). ... processed into short 21-23 nucleotide RNAs termed ...
Breaking Medicine Technology:Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 2Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 3Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 4Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 5Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 2Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 3Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 4Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 5Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 2Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 3
... 2011 Misonix, Inc. (NASDAQ: MSON ... and markets innovative therapeutic ultrasonic products worldwide for ... surgery and other surgical and medical applications, announced ... Symposium on Advances in Skin and Wound Care ...
... Every year thousands of children are hospitalized — and ... (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) Teens share stolen prescription ... pills that look like candy. In this ... can prevent harm by locking your medicine up. ...
Cached Medicine Technology:Misonix Exhibits at 26th Annual Clinical Symposium on Advances in Skin and Wound Care 2Misonix Exhibits at 26th Annual Clinical Symposium on Advances in Skin and Wound Care 3
(Date:5/29/2015)... (PRWEB) May 29, 2015 Mediaplanet has ... “beauty of protection”. Skin Health is a cross-platform ... within the markets of New York, Los Angeles, and ... 750,000 readers. Its digital counterpart will reach a national ... To read more the Skin Health campaign and Colorescience, ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 Healthpointe ... consultations with specialists, physical therapy, and injections , ... mid back and/or lower back pain, Healthpointe has ... injections for herniated discs, disc protrusions and other ... , Healthpointe’s team of renowned surgeons are ...
(Date:5/29/2015)... Dr. Rodger Murphree, author of Treating ... now offering free weekly call in teleconferences each ... to reduce symptoms associated with fibromyalgia including chronic ... fog. , To find out more about ... in teleconferences simply go to http://www.endfibronow.com ...
(Date:5/29/2015)... May 29, 2015 Healthpointe’s electromyography ... to the Los Angeles County clinics including its ... are now being offered at all Healthpointe locations ... and San Bernardino County. , As the ... send electrical impulses throughout the body and ...
(Date:5/29/2015)... 2015 This is a professional ... the Naproxen industry.The report provides a basic overview ... industry chain structure. The Naproxen market ... development trends, competitive landscape analysis, and key regions ... well as manufacturing processes and cost structures are ...
Breaking Medicine News(10 mins):Health News:Mediaplanet Launches “Skin Health” Campaign Featuring Colorescience 2Health News:Healthpointe’s Pain Management Specialists Now Providing Lumbar Epidural Injections in Los Angeles County 2Health News:Healthpointe’s Pain Management Specialists Now Providing Lumbar Epidural Injections in Los Angeles County 3Health News:Healthpointe Is Now Offering EMG and NCV Diagnostics at All Clinics throughout Southern California. 2Health News:Naproxen Market Analysis For Global & China Regions 2020 Research Forecasts 2
... ReauthorizationWASHINGTON, Jan. 14 The following fact sheet was ... the House: Divided We Fail Partnership (AARP, Business Roundtable, ... "On behalf of Divided We Fail, we urge you ... Children,s Health Insurance Program (SCHIP). Our nation has a ...
... journal report:Study highlights:-- Cholesterol-lowering drug adherence drops with ... of going for 90 straight days without medication ... all co-payment group and twice as high in ... to the exempt group (received prescriptions without a ...
... Utilize MICROSPONGE(R) Delivery SystemCARLSBAD, Calif., Jan. 14 ... Micro Wash, the only prescription benzoyl ... delivery system, for the treatment of mild ... Wash contains 7% benzoyl peroxide.(Photo: http://www.newscom.com/cgi-bin/prnh/20090114/LA58962 ...
... Rehab MarketHOUSTON, Jan. 14 Anne Kieschnik, a complex ... joined Alliance Seating & Mobility (ASM), one ... Kieschnik is an Assistive Technology Professional (ATP) ... for ASM ( www.alliance-seating.com ) and is responsible for ...
... access journal reportStudy highlights:, , ... odds of having cardiovascular disease within 10 years may not be ... Most adults 50 years and younger have a low 10-year risk ... disease. , Researchers suggest using ...
... blood-sucking critters, resistance to insecticides increasing in urban areas , , ... insecticides appears to be why bed bugs are making a ... , Bed bugs in New York City, where infestations have ... mutations that weaken the effect of the pyrethroid toxins, such ...
Cached Medicine News:Health News:Health Care For 11 Million Children 2Health News:Health Care For 11 Million Children 3Health News:Health Care For 11 Million Children 4Health News:Co-Payment Increases Result in Gaps in Veterans' Prescription Usage 2Health News:Co-Payment Increases Result in Gaps in Veterans' Prescription Usage 3Health News:Co-Payment Increases Result in Gaps in Veterans' Prescription Usage 4Health News:SkinMedica(R) Launches NeoBenz(R) Micro Wash for Acne 2Health News:SkinMedica(R) Launches NeoBenz(R) Micro Wash for Acne 3Health News:Veteran Rehab Specialist, Anne Kieschnik, Joins Fast-Growing Alliance Seating & Mobility In Texas 2Health News:Veteran Rehab Specialist, Anne Kieschnik, Joins Fast-Growing Alliance Seating & Mobility In Texas 3Health News:Half of Adults 50 and Younger With Low 10-Year Risk of CVD Have High Lifetime Risk 2Health News:Half of Adults 50 and Younger With Low 10-Year Risk of CVD Have High Lifetime Risk 3Health News:Bed Bugs, Nearly Eradicated, Make a Comeback 2
... vascular tests for assessing peripheral vascular disease. With the Portable ABI Kit, you get the basic equipment ... ... ... The ankle-arm pressure index (also known as the Ankle/Brachial ...
... Clinitek Microalbumin Strips provide albumin, creatinine ... The Clinitek Microalbumin product is useful to ... or hypertension in order to detect early ... elevation of the urinary albumin excretion rate, ...
... today's busy physician's office environment, ... contribute to timing errors and ... strips are read visually. Studies ... is performed with an instrument, ...
... Ultra device consists of a non-compliant balloon ... mounted longitudinally on its outer surface. When ... the atherotomes score the plaque, creating initiation ... to as Atherotomy, allows dilatation of the ...
Medicine Products: